Hyperglycemia News and Research RSS Feed - Hyperglycemia News and Research

Hyperglycemia occurs when you have a higher than usual level of glucose in your blood. This can happen shortly after you have eaten a big meal and is not a problem if your glucose level returns to normal. Cells remove glucose from the blood in response toinsulin. If your pancreas doesn't make enough insulin, glucose can't enter the cells and remains in the blood. Blood glucose levels can also get too high if cells areunable to respond to insulin properly (insulinresistance). Without glucose, your cells are unable to make energy and can't function properly.
Researchers investigate link between diet, obesity-linked Type 2 diabetes, and spinal disc degeneration

Researchers investigate link between diet, obesity-linked Type 2 diabetes, and spinal disc degeneration

Can a diet high in processed fat and sugar and Type 2 diabetes cause degeneration of intervertebral discs in the spine? If so, what is happening, and can it be prevented? As part of an ongoing collaboration between Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai - a partnership that draws upon the expertise of both schools to address significant health problems - researchers hope to answer those questions by investigating the link between diet, obesity-linked Type 2 diabetes, and intervertebral disc degeneration. [More]
Diabetes mellitis coexisting with solid-organ malignancies linked to hospitalization risks

Diabetes mellitis coexisting with solid-organ malignancies linked to hospitalization risks

Future Science Group today announced the publication of a new article in Future Science OA examining the effects of diabetes on hospitalization risk, chances of multiple admissions, and length of hospitalization stay, for patients suffering from solid-organ malignancies such as breast, colorectal, lung and pancreas, among others. [More]
Dexcom launches new cloud-based solution for secure sharing of CGM data between physicians and patients

Dexcom launches new cloud-based solution for secure sharing of CGM data between physicians and patients

Dexcom, Inc., a leader in continuous glucose monitoring (CGM) for patients with diabetes, today announced the availability of enhanced data sharing features for physician and patient users of the Dexcom CLARITY diabetes management solution. [More]
Normoglycaemia key to improved neurological outcome after paediatric stroke

Normoglycaemia key to improved neurological outcome after paediatric stroke

Achieving normal blood glucose concentrations may be important in preventing poor neurological outcomes in children following acute arterial ischemic stroke, a retrospective review indicates. [More]
HbA1C test can effectively detect hidden diabetes among hyperglycemia patients

HbA1C test can effectively detect hidden diabetes among hyperglycemia patients

A retrospective review of medical records found the HbA1C test, commonly used to diagnose and manage diabetes, can effectively detect hidden disease among hospital patients with hyperglycemia, commonly known as high blood sugar. [More]
Four major phenotypes may help improve prediction, prevention of cardiometabolic risk in prediabetes

Four major phenotypes may help improve prediction, prevention of cardiometabolic risk in prediabetes

Prediabetes is associated with increased risk of diabetes, cardiovascular disease, dementia and cancer. However, the disease risk considerably varies among subjects. [More]
Potential new intraocular treatment based on RAS manipulation can prevent or reverse diabetic retinopathy

Potential new intraocular treatment based on RAS manipulation can prevent or reverse diabetic retinopathy

Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on manipulating the renin angiotensin system (RAS) that both prevents and reverses some characteristics of diabetic retinopathy in a mouse model. [More]
Cancerous lung tumors can alter metabolism by hijacking circadian mechanisms

Cancerous lung tumors can alter metabolism by hijacking circadian mechanisms

University of California, Irvine scientists who study how circadian rhythms - our own body clocks - control liver function have discovered that cancerous lung tumors can hijack this process and profoundly alter metabolism. [More]
Integrating fiber optic biosensor into microfluidic chip may help in early diagnosis of diabetes

Integrating fiber optic biosensor into microfluidic chip may help in early diagnosis of diabetes

Insulin deficiency and hyperglycemia are two well-known culprits behind diabetes, both of which are reflected in blood glucose concentrations. Now, researchers are working to create ultrasensitive lab-on-a-chip devices to quickly measure glucose concentrations with the goal of developing device for early diagnosis and prevent of diabetes [More]
Study points to novel way to treat diabetes in some patients

Study points to novel way to treat diabetes in some patients

Blocking the hormone that raises sugar levels in the blood could increase insulin levels while keeping blood sugar levels down. [More]
Gleevec could be novel therapeutic agent for type 2 diabetes

Gleevec could be novel therapeutic agent for type 2 diabetes

The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic myeloid leukemia (CML). However, researchers have stumbled onto another possible use for it, curing type 2 diabetes. [More]
Preventing blindness through portable eye examinations: an interview with Dr Mario Ettore Giardini

Preventing blindness through portable eye examinations: an interview with Dr Mario Ettore Giardini

The number of blind people is high. In 2010, the World Health Organisation estimated that, throughout the world, approximately 39 million people are blind. [More]
New article explores effect of frailty on natural history of diabetes

New article explores effect of frailty on natural history of diabetes

Future Science Group today announced the publication of a new article in Future Science OA, reporting data that explore the effect of frailty on the natural history of diabetes and the implications it will have for therapeutic plans in older people. [More]
Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. [More]
Study reveals association between DNA methylation and type 2 diabetes

Study reveals association between DNA methylation and type 2 diabetes

Researchers from the Hospital del Mar Medical Research Institute have found an epigenetic mechanism implicated in the regulation of blood sugar. The study, published in the journal Molecular Human Genetics, reveals that the methylation of the TXNIP gene is associated with diabetes mellitus type 2 and, in particular, average blood glucose levels. [More]
American Diabetes Association issues statement to address diabetes management in LTC facilities

American Diabetes Association issues statement to address diabetes management in LTC facilities

The care of adults over age 65 with type 2 diabetes is a growing concern: the prevalence of diabetes is highest in this age group and is expected to grow as the U.S. population ages, with many needing care at long-term care (LTC) facilities. [More]
Lilly receives FDA approval for Humulin R U-500 KwikPen

Lilly receives FDA approval for Humulin R U-500 KwikPen

The U.S. Food and Drug Administration has approved Eli Lilly and Company's Humulin R U-500 KwikPen(insulin human injection) 500 units/mL, a pre-filled device containing Humulin R U-500, a highly concentrated formulation of insulin. [More]
Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the so-called artificial pancreas system performs in patients as hoped, it could lead to commercial trials and eventual regulatory approval in the United States and abroad. [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Mayo Clinic researchers report national trend toward overtesting HbA1C levels in diabetes patients

Mayo Clinic researchers report national trend toward overtesting HbA1C levels in diabetes patients

In a study released online today in The BMJ, researchers from Mayo Clinic report a national trend toward overtesting glycated hemoglobin (HbA1C) levels in adult patients with Type 2 diabetes. [More]
Advertisement